High water content biomedical devices
A biomedical device is disclosed. The biomedical device includes a polymerization product of a biomedical device-forming mixture containing (a) one or more grafted glycosaminoglycan polymers including a glycosaminoglycan having a polymer backbone and one or more side chains comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone, and (b) one or more non-silicone biomedical device-forming monomers.
1 . A biomedical device comprising a polymerization product of a biomedical device-forming mixture comprising:
(a) one or more grafted glycosaminoglycan polymers comprising a glycosaminoglycan having a polymer backbone and one or more side chains comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone, and
(b) one or more non-silicone biomedical device-forming monomers;
wherein the biomedical device has an equilibrium water content of at least about 80 wt. % and an oxygen permeability (Dk) of at least about 60.
2 . The biomedical device according to claim 1 , wherein the glycosaminoglycan is selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, heparosan, hyaluronan, and hyaluronic acid or a salt thereof.
3 . The biomedical device according to claim 1 , wherein the one or more grafted glycosaminoglycan polymers have a degree of grafting ranging from about 2 to about 30%.
4 . The biomedical device according to claim 1 , wherein the ethylenically unsaturated reactive-containing residue is a methacrylate-containing residue.
5 . The biomedical device according to claim 4 , wherein the one or more grafted glycosaminoglycan polymers have a degree of methacrylation ranging from about 0.5 percent to about 50 percent.
6 . The biomedical device according to claim 1 , wherein the one or more non-silicone biomedical device-forming monomers are selected from the group consisting of an unsaturated carboxylic acid, an acrylamide, a vinyl lactam, a (meth)acrylic acid, a hydroxyl-containing-(meth)acrylate, a hydrophilic vinyl carbonate, a hydrophilic vinyl carbamate monomer, a hydrophilic oxazolone monomer, and mixtures thereof.
7 . The biomedical device according to claim 1 , wherein the biomedical device-forming mixture further comprises one or more crosslinking agents.
8 . The biomedical device according to claim 1 , wherein the biomedical device-forming mixture further comprises one or more components selected from the group consisting of a wetting agent, a surfactant and an ultraviolet (UV) blocker.
9 . The biomedical device according to claim 1 , wherein the biomedical device-forming mixture comprises:
about 0.1 to about 2 wt. %, based on the total weight of the biomedical device-forming mixture, of the one or more grafted glycosaminoglycan polymers; and
about 30 to about 90 wt. %, based on the total weight of the biomedical device-forming mixture, of the one or more non-silicone biomedical device-forming monomers.
10 . The biomedical device according to claim 1 , having a water content of at least about 80 wt. % to about 90 wt. % and an oxygen permeability (Dk) of at least about 60 to about 80.
11 . The biomedical device according to claim 1 , which is one of a contact lens, an intraocular lens and a hydrogel.
12 . A method for making a biomedical device comprising:
(a) providing a biomedical device-forming mixture comprising (i) one or more grafted glycosaminoglycan polymers comprising a glycosaminoglycan having a polymer backbone and one or more side chains comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone, and (ii) one or more non-silicone biomedical device-forming monomers;
(b) subjecting the mixture to polymerization conditions to provide a polymerized biomedical device; and
(c) hydrating the polymerized biomedical device;
wherein the biomedical device has an equilibrium water content of at least about 80 wt. % and an oxygen permeability (Dk) of at least about 60.
13 . The method according to claim 12 , wherein the glycosaminoglycan is selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, heparosan, hyaluronan, and hyaluronic acid or a salt thereof, and the one or more non-silicone biomedical device-forming monomers are selected from the group consisting of an unsaturated carboxylic acid, an acrylamide, a vinyl lactam, (meth)acrylic acid, a hydroxyl-containing-(meth)acrylate, a hydrophilic vinyl carbonate, a hydrophilic vinyl carbamate monomer, a hydrophilic oxazolone monomer, and mixtures thereof.
14 . The method according to claim 12 , wherein the ethylenically unsaturated reactive-containing residue is a methacrylate-containing residue, and the grafted glycosaminoglycan polymer has a degree of methacrylation ranging from about 0.5 percent to about 50 percent.
15 . The method according to claim 12 , wherein the biomedical device-forming mixture further comprises one or more crosslinking agents.
16 . The method according to claim 12 , wherein the biomedical device-forming mixture comprises:
about 0.1 to about 2 wt. %, based on the total weight of the biomedical device-forming mixture, of the one or more grafted glycosaminoglycan polymers; and
about 30 to about 90 wt. %, based on the total weight of the biomedical device-forming mixture, of the one or more non-silicone biomedical device-forming monomers.
17 . The method according to claim 12 , wherein the biomedical device is one of a contact lens, an intraocular lens and a hydrogel.
18 . The biomedical device according to claim 1 , wherein the glycosaminoglycan has a weight average molecular weight of from about 40,000 to about 3,000,000 Daltons.
19 . The biomedical device according to claim 1 , which is one of a contact lens, an intraocular lens and a hydrogel, and wherein the glycosaminoglycan is hyaluronic acid or a salt thereof, the ethylenically unsaturated reactive-containing residue is a methacrylate-containing residue, and the one or more non-silicone biomedical device-forming monomers are selected from the group consisting of an unsaturated carboxylic acid, an acrylamide, a vinyl lactam, (meth)acrylic acid, a hydroxyl-containing-(meth)acrylate, a hydrophilic vinyl carbonate, a hydrophilic vinyl carbamate monomer, a hydrophilic oxazolone monomer, and mixtures thereof.
20 . The biomedical device according to claim 19 , wherein the biomedical device-forming mixture further comprises one or more components selected from the group consisting of a wetting agent, a surfactant and an ultraviolet (UV) blocker.